A Phase Ⅲ Clinical Study of SNA02-48 Injection
NCT07633119
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
600
Enrollment
INDUSTRY
Sponsor class
Conditions
Tetanus
Interventions
DRUG:
SNA02-48
DRUG:
Human tetanus immunoglobulin (HTIG)
Sponsor
Sinovac Life Sciences Co., Ltd.